Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yonghe Medical Group CoFRA:L97 +3.88%84 Debt-to-Equity is 0.53 as of Jun. 2026, which is 40% below its 10-year median of 0.89. GuruFocus rates FRA:L97 with a GF Score™ of 84/100 and a GF Value™ of €0.21. The stock has 7 warning signs investors should review. Among 559 Healthcare Providers & Services companies, Yonghe Medical Group Co ranks worse than 58.68% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Yonghe Medical Group Co's Debt-to-Equity or its related term are showing as below:
FRA:L97'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.53 Med: 0.89 Max: 2.31
Current: 0.53
During the past 8 years, the highest Debt-to-Equity Ratio of Yonghe Medical Group Co was 2.31. The lowest was 0.53. And the median was 0.89.
FRA:L97's Debt-to-Equity is ranked worse than 58.68% of 559
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs FRA:L97: 0.53
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Yonghe Medical Group Co Debt-to-Equity Related Terms
Yonghe Medical Group Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L97 vs HCA, THC, DVA: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, Yonghe Medical Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yonghe Medical Group Co Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yonghe Medical Group Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Yonghe Medical Group Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yonghe Medical Group Co (FRA:L97) has a Debt-to-Equity of 0.53 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Yonghe Medical Group Co and its competitors. This is 40% below median its historical median of 0.89. Over the past decade, Yonghe Medical Group Co's Debt-to-Equity has ranged from 0.53 to 2.31. According to the industry distribution chart, Yonghe Medical Group Co ranks #328 out of 559 companies in the Healthcare Providers & Services industry, placing it in the top 58.7%.
Is Yonghe Medical Group Co's Debt-to-Equity too high?
Yonghe Medical Group Co's current Debt-to-Equity of 0.53 is 40% below median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 2.31. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Yonghe Medical Group Co's value of 0.53 is 26.2% above this industry median. Based on the distribution chart, Yonghe Medical Group Co ranks #328 out of 559 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Yonghe Medical Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Yonghe Medical Group Co's Debt-to-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Yonghe Medical Group Co ranks #328 out of 559 companies for Debt-to-Equity. This places Yonghe Medical Group Co in the lower half of its industry. The industry median Debt-to-Equity is 0.42. Yonghe Medical Group Co's value of 0.53 is 26.2% above this benchmark. Historically, Yonghe Medical Group Co's own Debt-to-Equity has ranged from 0.53 to 2.31 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.42, Yonghe Medical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yonghe Medical Group Co's current Debt-to-Equity of 0.53 is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Yonghe Medical Group Co and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yonghe Medical Group Co's current Debt-to-Equity is 0.53, which is 40% below median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yonghe Medical Group Co stock overvalued right now?
Yonghe Medical Group Co (FRA:L97) has a current Debt-to-Equity of 0.53. The stock's GF Value™ is €0.21, compared to a current price of €0.27 — trading 27.6% above its estimated fair value. The current Debt-to-Equity is 0.53, which is 40% below median its 10-year median of 0.89 and 26.2% above the Healthcare Providers & Services industry median of 0.42. Yonghe Medical Group Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Yonghe Medical Group Co (FRA:L97), the current Debt-to-Equity is 0.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yonghe Medical Group Co (FRA:L97) Overvalued in 2026?
Based on GuruFocus' analysis, Yonghe Medical Group Co stock appears to be overvalued.
The current stock price of €0.27 is trading 27.6% above its estimated GF Value™ of €0.21.
Key valuation signals for FRA:L97:
Debt-to-Equity: 0.53 (40% below median its 10-year median of 0.89)
GF Value™: €0.21 vs. price of €0.27 (27.6% above fair value)
Industry Position: 26.2% above the Healthcare Providers & Services median (#328 of 559)
No single metric tells the full story. See the FRA:L97 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yonghe Medical Group Co Ltd is a medical group in China that specializes in providing hair-related healthcare services. The company is principally engaged in the provision of hair transplant services. The company generated the majority of its revenue from hair transplant services. The company offers one-stop hair-related healthcare services covering hair transplants, medical hair care, routine hair restoration, and other ancillary services.
84GF Score
Get the complete analysis for FRA:L97
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L97 has been successfully added to your 
